- Global Pharma News & Resources

Global Liver Cancer Drugs Market 2019-2023 - Market will Register a CAGR of Over 10% -

The "Global Liver Cancer Drugs Market 2019-2023" report has been added to's offering.

The liver cancer drugs market will register a CAGR of over 10% by 2023.

Long-term survival requires advanced diagnostic methods, which may detect small tumors that are often present in asymptomatic patients. Elevated levels of the serum marker alfa-fetoprotein are often indicative of the disease when combined with ultrasonography. Liver biopsy is also a diagnostic method used by many professionals. Various serologic markers may help to improve surveillance accuracy. Computed tomography and magnetic resonance imaging are currently used for liver imaging for surveillance. However, they can be used for the diagnosis and staging of liver cancer.

Only curative option is surgical resection and transplantation

The surgery is often associated with high recurrence rate of tumors. Patients with recurrent tumors are evaluated for liver transplantation. However, a major challenge for liver transplantation is the number of insufficient donor livers. Another challenge is that the disease is often diagnosed in the advanced stage when surgery or transplantation may not be feasible.

Competitive Landscape

The market appears to be concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Market Landscape

Part 04: Pipeline Analysis

Part 05: Market Sizing

Part 06: Five Forces Analysis

Part 07: Market Segmentation By Type

Part 08: Customer Landscape

Part 09: Geographic Landscape

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

  • Bayer
  • Bristol-Myers Squibb
  • Eisai
  • Merck
  • Ono Pharmaceutical

For more information about this report visit

View source version on

Editor Details

Last Updated: 29-Jan-2019